All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked: After the latest follow-up of the MASTER trial, can we safely implement minimal residual disease (MRD)-guided frontline treatment in the clinic?
MASTER trial: Can we safely implement MRD-guided frontline treatment in the clinic?
Costa discusses the recent results of the single-arm, phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.
Your opinion matters
MASTER trial | Monoclonal antibody-based quadruplet regimen (Dara-KRd) with MRD–based response-adapted therapy in patients with NDMM
Summary of Abstract #860 presented at ASH | Monoclonal antibody-based quadruplet regimen (daratumumab-KRd) with...
Is CC-93269, a novel BCMA T-cell engager, safe and efficacious for patients with RRMM?
Luciano J. Costa, University of Alabama at Birmingham, Birmingham, US, answers the question: Is CC-93269, a novel BCMA T-cell engager, safe and efficacious for...
Subscribe to get the best content related to multiple myeloma delivered to your inbox